Seeking men and women whose non-small cell lung cancer responded or remained stable to platinum-based chemotherapy and are currently taking pembrolizumab for a study of an investigational drug combination for maintenance therapy.
Seeking men and women aged 18 and older with colon or rectal cancer than has spread to other parts of their body (metastatic) for a study of an investigational drug added to the standard chemotherapy treatment.
Seeking men and women whose non-small cell lung cancer (NSCLC) has spread outside the lungs, and has a change in the gene called EGFR (epidermal growth factor receptor) and has not yet been treated for a study of an investigational drug combination.
Seeking men and women with hormone receptor positive/ human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced inoperable or metastatic breast cancer for a study of an investigational drug combination.
Seeking men and women whose non-small cell lung cancer has spread or stopped responding to treatment and whose cancer has been tested and found to have a specific mutation in the KRAS gene known as KRAS (G12C) for a study of an investigational drug for targeted treatment against the KRAS (G12C) mutation.
Seeking men and women who have been diagnosed since January 1, 2020, with metastatic non-small cell lung cancer and have been or will be treated with immunotherapy, chemotherapy or a combination of the two for a study to develop a tool to help guide treatment decisions.